Delpor Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $7.2M

  • Investors
  • 11

Delpor General Information

Description

Developer of drug delivery implant technologies designed to create long-acting pharmaceutical formulations. The company's technologies allow the sustained release of drugs from a small, non-mechanical, subcutaneous implant device which can be implanted through a simple, in-office, procedure using local anesthetic and without the need for any surgical sutures, enabling patients to have improved medication adherence, safety, and efficacy, as well as convenience when frequent injections are required.

Contact Information

Website
www.delpor.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 150 North Hill Drive
  • Suite 25
  • Brisbane, CA 94005
  • United States
+1 (415)
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Other Devices and Supplies
Vertical(s)
Life Sciences
Corporate Office
  • 150 North Hill Drive
  • Suite 25
  • Brisbane, CA 94005
  • United States
+1 (415)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Delpor Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Later Stage VC 01-Aug-2023 $7.2M Completed Clinical Trials - Phase 1
13. Grant 01-Jan-2021 Completed Clinical Trials - Phase 1
12. Grant 09-Oct-2019 Completed Clinical Trials - Phase 1
11. Grant 30-Sep-2019 Completed Clinical Trials - Phase 1
10. Grant 15-Apr-2019 Completed Clinical Trials - Phase 1
9. Later Stage VC (Series B) 30-Jul-2018 Completed Clinical Trials - Phase 1
8. Grant 14-Jun-2017 Completed Clinical Trials - Phase 1
7. Accelerator/Incubator 19-Dec-2016 Completed Clinical Trials - Phase 1
6. Later Stage VC (Series A) 01-Dec-2015 $2.5M $3.4M Completed Clinical Trials - Phase 1
5. Grant 14-Oct-2014 $220K $900K Completed Startup
To view Delpor’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Delpor Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of drug delivery implant technologies designed to create long-acting pharmaceutical formulations. The company'
Drug Delivery
Brisbane, CA
12 As of 2023

PA
 

Austin, TX
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Delpor Competitors (12)

One of Delpor’s 12 competitors is OptiNose, a Private Equity-Backed company based in PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
OptiNose Private Equity-Backed PA
Mati Therapeutics Venture Capital-Backed Austin, TX
LTS Lohmann Therapie-Systeme Private Equity-Backed Andernach, Germany
Lyra Therapeutics Formerly VC-backed Watertown, MA
Claris Bio Venture Capital-Backed Jersey City, NJ
You’re viewing 5 of 12 competitors. Get the full list »

Delpor Patents

  • 71

    Total Documents Applications and Grants

  • Total Patents Families

  • 32

    Granted

  • 22

    Pending

  • Expiring in next 12 mo

Delpor Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4482473-A1 Implantable devices for the sustained delivery of an opioid antagonist and methods for treating inflammatory, neuroinflammatory and metabolic disorders Pending 22-Feb-2022
US-20250152503-A1 Implantable devices for the sustained delivery of an opioid antagonist and methods for treating inflammatory, neuroinflammatory and metabolic disorders Pending 22-Feb-2022
AU-2020340385-A1 Compositions for small molecule therapeutic agent compounds Pending 28-Aug-2019
CA-3149545-A1 Compositions for small molecule therapeutic agent compounds Pending 28-Aug-2019
EP-4021406-A1 Compositions for small molecule therapeutic agent compounds Pending 28-Aug-2019 A61K31/485
To view Delpor’s complete patent history, request access »

Delpor Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Delpor Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
SeedFolio Venture Capital Minority
National Institute of Mental Health Government
National Institute on Drug Abuse (NIDA) Government
National Institutes of Neurological Disorders and Stroke Government
National Institutes of Health Government
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial

Delpor FAQs

  • When was Delpor founded?

    Delpor was founded in 2009.

  • Where is Delpor headquartered?

    Delpor is headquartered in Brisbane, CA.

  • What is the size of Delpor?

    Delpor has 12 total employees.

  • What industry is Delpor in?

    Delpor’s primary industry is Drug Delivery.

  • Is Delpor a private or public company?

    Delpor is a Private company.

  • What is Delpor’s current revenue?

    The current revenue for Delpor is .

  • How much funding has Delpor raised over time?

    Delpor has raised $14M.

  • Who are Delpor’s investors?

    SeedFolio, National Institute of Mental Health, National Institute on Drug Abuse (NIDA), National Institutes of Neurological Disorders and Stroke, and National Institutes of Health are 5 of 11 investors who have invested in Delpor.

  • Who are Delpor’s competitors?

    OptiNose, Mati Therapeutics, LTS Lohmann Therapie-Systeme, Lyra Therapeutics, and Claris Bio are some of the 12 competitors of Delpor.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »